All In Biotech

Free tool

FAERS Monitor: Sohonos

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 215559 or its brand name (Sohonos, Palovarotene). Reports on generic versions are filed under their own applications.

Reports

71

Serious

38

54% of reports

Hospitalization

9

Death reported

2

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • condition aggravated33
  • off label use17
  • dry skin14
  • product dose omission issue14
  • fibrodysplasia ossificans progressiva10
  • pruritus10
  • skin exfoliation10
  • alopecia6
  • rash6
  • drug ineffective5
  • cross sensitivity reaction4
  • dyspepsia3
  • fall3
  • nausea3
  • pain3

Reports by year received

View as table
YearReports
20223
20233
202417
202522
202626

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,088 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
fibrodysplasia ossificans progressivaSignal10211811.897342.21,115,090
cross sensitivity reactionSignal41222.8471.03,723
skin exfoliationSignal1035.119.8299
condition aggravatedSignal3332.225.1979
dry skinSignal1431.119.4380
product dose omission issueSignal1414.18.8160
alopeciaSignal69.14.236
dyspepsiaSignal39.03.014
pruritusSignal107.74.353
off label useSignal175.83.865
rashSignal64.11.911
fall32.70.92
pain31.40.50
drug ineffective51.10.50
nausea31.10.40

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.